The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating
Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial
Home ยป
Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions
COVID-19 vaccines have led to drastic decreases in the number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases and
A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines
Antibodies elicited by natural infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or by vaccines against coronavirus disease
Study finds lower antibody activity against delta variant at single vaccine dose, but vaccines still work
Chris Whitty, the chief medical officer for England, recently announced that the delta variant is no longer of concern because
Rapid mRNA vaccination effectively controls SARS-CoV-2 transmission in long-term care facilities
Vaccine rollouts all over the world are aimed at cutting short the coronavirus disease 2019 (COVID-19) pandemic by inducing antibody-mediated
Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape
The current pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered an
SARS-CoV-2 variants with E484K mutation show mRNA vaccine-induced antibody evasion
A recent study by researchers in Switzerland found that the Pfizer-BioNTech mRNA vaccine had limited efficacy in identifying mutated receptor-binding
Why does convalescent plasma therapy for severe COVID-19 show mixed success?
Treatment modalities against the coronavirus disease 2019 (COVID-19) pandemic are limited in efficacy. This has led many centers to use
Why does convalescent plasma therapy for severe COVID-19 show mixed success?
Treatment modalities against the coronavirus disease 2019 (COVID-19) pandemic are limited in efficacy. This has led many centers to use
What is a protective neutralizing antibody titer against SARS-CoV-2 infection?
Caused by the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic continues